Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7 TCR T Cell Immunotherapy for High-Grade CIN
NCT04411134Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- May 2020
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial of KITE-439 in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety of intralesional injection of E7 TCR T cell therapy at 3 months. Planned start May 2020; status: withdrawn.
02
Drugs
KITE-439
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT04411134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411134.